COMPANY PROFILE

Genomind

A mental health biotechnology and digital service company bringing innovative solutions to personalized mental healthcare and wellness through genetic testing

Upper Merion Township, United StatesFounded 2009Biotech & Life Sciences

Valuation $100–250M Last recorded · 2020

Revenue $10–50M Latest reported FY

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Genomind

Genomind operates in the mental health sector, providing genetic testing services aimed at improving mental health outcomes. The company serves healthcare providers, patients, and mental health professionals by offering insights into genetic predispositions related to mental health. Genomind's core product is a genetic test that identifies genetic markers associated with mental health conditions, which helps in making more informed prescribing decisions. The company operates on a B2B and B2C model, generating revenue through the sale of genetic testing kits and associated services. The market it operates in includes healthcare, biotechnology, and personalized medicine sectors. Genomind's business model focuses on providing actionable genetic insights that can lead to better mental health treatment plans, thereby enhancing patient outcomes and satisfaction.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2009
Headquarters: Upper Merion Township, United States
Employees: 59
Open positions: 1
Dealroom signal: 65.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Testing, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, medical testing, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES DOther financing	Dec 2020	$4.9M	$103M	Claritas Capital · The Dozoretz Trust	—
LATE VCOther financing	Sep 2020	$21M	$82M	Undisclosed	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Genomind website traffic

Latest recorded traffic for Genomind is 59K monthly website visits, up 47.5% over the last three months. Genomind's team declined 9.2% over the past year.

Latest monthly visits59K 3-month web change+47.5% 1-year team growth-9.2%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MLMedGenome LabsA genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome	Foster City, United States	Operational	1,013	$233M	$275M
SESea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology	Vila do Bispo, Portugal	Operational
BRBrainPlottingBrainPlotting propose a premium service with fresh Human models for brain PK, toxicological testing and pharmacological testing	Paris, France	Operational
GGGastro GirlFirst patient-centric digital health platform for individuals living with gastrointestinal (gi) symptoms and conditions	Falls Church, United States	Operational
BUBerkeley UltrasoundTools for neurological researches focusing on development transcranial ultrasound stimulation	San Francisco, United States	Operational
RERegeneMedDrugs by providing integrated, high-throughput platforms incorporating engineered human tissue-based assays	San Diego, United States	Operational
CECellartisDevelops human embryonic stem cells and technology for drug discovery research, toxicity testing and regenerative medicine	Göteborgs Stad, Sweden	Acquired
INInVitaeBringing comprehensive, affordable, expert genetic insights into mainstream medical care. To read our community guidelines, visit https://t.co/mWqD4UMDer	San Francisco, United States	Acquired